August 2026
Psilocybin
What August 2026's 4 new studies found, synthesized from the papers below. All Psilocybin research →
The synthesis
Synthesized from 4 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, then ranked by relevance.
Research published in August 2026 indicates that standard-dose psilocybin (25 mg) is effective for major depressive disorder, with meta-analytic evidence showing large reductions in depressive symptoms and higher response/remission rates at 2-3 and 6-12 weeks, though transient headaches and nausea occur. Microdosing evidence remains low-certainty, with some studies suggesting benefits but causal effects not established. Therapeutic alliance appears to facilitate the psychedelic experience, but the experience itself has stronger direct effects on depression outcomes. A review on tinnitus proposes mechanistic plausibility but lacks clinical data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing 2026 | systematic review | 3262 | Mixed | Some studies suggest microdosing may improve well-being, mental health, cognition, and other outcomes, but evidence is low certainty and causal effects cannot be inferred; motivations were mostly non-medical (86%) and adverse events rarely reported. |
| The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis. 2026 | observational cohort with correlation and path analysis | 79 | Supports | Therapeutic alliance facilitated the psychedelic experience, but the psychedelic experience itself had stronger direct effects on depression outcomes than the alliance. |
| Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus. 2026 | review | Unclear | Argues that psilocybin's activation of 5-HT2A receptors and subsequent neuroplasticity mechanisms may synergistically regulate excitatory and inhibitory neurotransmitter systems relevant to tinnitus. | |
| Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis. 2026 | systematic review and meta-analysis | Supports | Standard-dose psilocybin was superior to control in reducing depressive symptoms and produced higher response and remission rates at 2-3 weeks and 6-12 weeks post-treatment, with lower all-cause discontinuation, though it was associated with transient headaches and nausea. |
Some studies suggest microdosing may improve well-being, mental health, cognition, and other outcomes, but evidence is low certainty and causal effects cannot be inferred; motivations were mostly non-medical (86%) and adverse events rarely reported.
systematic review Sample size: 3262
Therapeutic alliance facilitated the psychedelic experience, but the psychedelic experience itself had stronger direct effects on depression outcomes than the alliance.
observational cohort with correlation and path analysis Sample size: 79
Argues that psilocybin's activation of 5-HT2A receptors and subsequent neuroplasticity mechanisms may synergistically regulate excitatory and inhibitory neurotransmitter systems relevant to tinnitus.
review
Standard-dose psilocybin was superior to control in reducing depressive symptoms and produced higher response and remission rates at 2-3 weeks and 6-12 weeks post-treatment, with lower all-cause discontinuation, though it was associated with transient headaches and nausea.
systematic review and meta-analysis
Points of agreement
- Psilocybin shows potential therapeutic benefits for depression and possibly other conditions.
- The psychedelic experience itself appears central to therapeutic outcomes.
- Adverse events are generally transient and not severe.
Conflicts
- Microdosing evidence is low certainty and cannot confirm causal benefits, whereas standard-dose psilocybin shows robust effects in MDD.
- The role of therapeutic alliance is debated: one study found it facilitates the experience but has weaker direct effects on outcomes.
Gaps
- Durability of effects beyond 12 weeks is not established.
- Blinding and active placebo controls are limited in many trials.
- Long-term safety and adverse event profiles are not fully characterized.
- Mechanistic claims for tinnitus are theoretical and lack clinical validation.
- Microdosing research lacks standardized protocols and objective outcome measures.